To evaluate the time of response, sustained remission rate, and relapse rate of CD38 monoclonal antibody (Daratumumab) combined with SCT800 (rFVIII) in the treatment of hemophilia A adolescents and adults with high titer inhibitors.
Moderate or severe hemophilia A;
Aged 14-66 years old;
Inhibitor positive at 2 consecutive visits;
Inhibitor titer > 10 BU at the screening visit.
The patient has contraindications to drug ingredients or hamster protein allergy;
Suffering from other immune diseases or Using immunosuppressant IS to treat another disease(s);
Failed systemic ITI treatment in history;
Poor patients compliance;
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor
Sinocelltech Ltd.
Collaborator